Pages that link to "Q36151488"

The following pages link to Tuberculosis vaccine development; from mouse to man. (Q36151488):

Displaying 33 items.

• Immunodominant tuberculosis CD8 antigens preferentially restricted by HLA-B (Q33300130) (← links)
• Chimeric flagellin expressed by Salmonella typhimurium induces an ESAT-6-specific Th1-type immune response and CTL effects following intranasal immunization (Q33577674) (← links)
• Recent progress in adjuvant discovery for peptide-based subunit vaccines (Q34033780) (← links)
• The secreted lipoprotein, MPT83, of Mycobacterium tuberculosis is recognized during human tuberculosis and stimulates protective immunity in mice (Q34261521) (← links)
• Human Mycobacterium tuberculosis CD8 T Cell Antigens/Epitopes Identified by a Proteomic Peptide Library (Q34785626) (← links)
• Human CD8+ T cells from TB pleurisy respond to four immunodominant epitopes in Mtb CFP10 restricted by HLA-B alleles (Q35070059) (← links)
• Preclinical testing of new vaccines for tuberculosis: a comprehensive review (Q36247723) (← links)
• DNA polymorphisms in the pepA and PPE18 genes among clinical strains of Mycobacterium tuberculosis: implications for vaccine efficacy. (Q36313933) (← links)
• The TB-specific CD4(+) T cell immune repertoire in both cynomolgus and rhesus macaques largely overlap with humans (Q36636763) (← links)
• Current status of TB vaccines (Q36744717) (← links)
• Construction of an Expression Vector Containing Mtb72F of Mycobacterium tuberculosis (Q36793706) (← links)
• Tuberculosis: vaccine and drug development (Q36872636) (← links)
• DNA vaccines against mycobacterial diseases (Q36895737) (← links)
• Heterologous boost vaccines for bacillus Calmette-Guérin prime immunization against tuberculosis (Q36899073) (← links)
• Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis (Q36982831) (← links)
• Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys (Q37114828) (← links)
• Tuberculosis: vaccines in the pipeline (Q37194790) (← links)
• TB vaccines: current status and future perspectives (Q37435926) (← links)
• Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects (Q37461371) (← links)
• Use of defined TLR ligands as adjuvants within human vaccines. (Q37825528) (← links)
• Current adjuvants and new perspectives in vaccine formulation. (Q37909424) (← links)
• Tools for cellular immunology and vaccine research the in the guinea pig: monoclonal antibodies to cell surface antigens and cell lines (Q38028233) (← links)
• Adjuvants containing natural and synthetic Toll-like receptor 4 ligands (Q38124063) (← links)
• Antigens for CD4 and CD8 T cells in tuberculosis (Q38213801) (← links)
• The candidate tuberculosis vaccine Mtb72F/AS02 in PPD positive adults: a randomized controlled phase I/II study (Q38460087) (← links)
• Comprehensive definition of human immunodominant CD8 antigens in tuberculosis (Q38849398) (← links)
• Tuberculosis vaccines: current progress (Q46410384) (← links)
• Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. (Q49161794) (← links)
• Immune responses in mice to Mycobacterium avium subsp. paratuberculosis following vaccination with a novel 74F recombinant polyprotein (Q58229512) (← links)
• Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis (Q80846388) (← links)
• Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis (Q82700313) (← links)
• Whole genome sequencing, analyses of drug resistance-conferring mutations, and correlation with transmission of Mycobacterium tuberculosis carrying katG-S315T in Hanoi, Vietnam (Q90950691) (← links)
• Developing Infectious Disease Strategies for the Developing World (Q91900543) (← links)